Related Experiment Video

Updated: Jun 24, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Improving the outcome of neonatal meningitis

Eva P Galiza1, Paul T Heath

  • 1Vaccine Institute, London, UK. egaliza@sgul.ac.uk

Current Opinion in Infectious Diseases
|April 1, 2009
PubMed
Abstract

Insights

Neonatal meningitis remains a significant threat, with mortality declining but morbidity persisting. Recent advances offer hope for better management and improved outcomes in affected infants.

Area of Science:

  • Neonatal infectious diseases
  • Pediatric neurology
  • Critical care medicine

Background:

  • Neonatal meningitis is a leading cause of infant mortality and long-term disability globally.
  • While mortality rates have decreased in developed nations, morbidity improvements lag.
  • This review examines recent progress in managing this critical condition.

Purpose of the Study:

  • To review recent advances in the management of neonatal meningitis.
  • To explore the implications of these advances for improving patient outcomes.
  • To identify areas for future research in neonatal meningitis treatment.

Main Methods:

  • Review of recent surveillance studies on neonatal meningitis pathogens and antibiotic resistance.
  • Analysis of theoretical data and studies from pediatric and adult sepsis for adjunctive therapies.
  • Synthesis of current evidence on early recognition, diagnosis, and supportive care strategies.

Main Results:

  • Surveillance data provide insights into causative pathogens, antibiotic susceptibility, and outcomes.
  • Evidence for optimal management strategies (e.g., fluid therapy, adjunctive treatments) is largely theoretical or extrapolated.
  • Early recognition, rapid diagnosis, and aggressive supportive care are crucial.

Conclusions:

  • Significant potential exists to enhance outcomes for infants with neonatal meningitis.
  • Further research is essential to define and validate key interventions.
  • More studies are needed to demonstrate the effectiveness of novel management approaches.

More Related Videos

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Related Concept Videos

Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: